-transparent.png){kind=logo}
Three flavans, daphnodorins A, B and C isolated from Dahpne odora THUNB. were tested for their abilities to inhibit human immunodeficiency virus type 1 (HIV-1(IIIB)) replication in MT-4 cells. The effective concentrations (EC50) of daphnodorins A, B and C against HIV-1-induced cytolysis were 0.26 +/- 0.08, 1.8 +/- 0.6 and 3.6 +/- 0.5 micrograms/ml, respectively. Also these three compounds showed inhibitory effects of p24 antigen in human peripheral blood lymphocytes. As compared with 2',3'-dideoxycytidine 5'-triphosphate (DDC-TP), daphnodorin A and daphnodorin C had relatively weak inhibitory effects on the reverse transcriptase of HIV-1, while daphnodorin B did not show any inhibitory effect at concentrations up to 1000 micrograms/ml. These three compounds showed marked inhibitory effects on syncytium formation between HIV-1(IIIB)-infected and uninfected MOLT-4 (clone 8) cells at 3-30 micrograms/ml without inducing cytotoxicity. The concentrations of the compounds blocking syncytium formation were consistent with the effective concentrations (EC50) against HIV-induced cytolysis of MT-4 cells. These results, differing from reverse transcriptase inhibitors, suggest that the daphnodorins exert their anti-HIV-1 activity through inhibition of early events of viral replication including adsorption of the virions to the cells or the subsequent entry.
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
May 1991,
The Journal of infectious diseases,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
October 1995,
Journal of virology,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
May 1999,
Archiv der Pharmazie,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
April 2001,
Journal of virology,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
January 2000,
Nucleosides, nucleotides & nucleic acids,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
January 1989,
Nucleic acids research,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
June 2002,
Human gene therapy,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
May 2005,
Biological & pharmaceutical bulletin,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
March 1994,
Journal of medical virology,
K Yusa, and
T Oh-hara, and
S Tsukahara, and
K Baba, and
M Taniguchi, and
M Kozawa, and
S Takeuchi, and
H Hara, and
T Tsuruo
November 1997,
The Journal of infectious diseases,
